Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Christopher James Walker"'
Autor:
Matthew D. Hellmann, Laura Q.M. Chow, Xiaohua Gong, Rebecca S. Heist, Gongfu Zhou, Michael S. Gordon, Lance Leopold, Mark M. Awad, Christopher James Walker, Edward Cha, Scott N. Gettinger
Publikováno v:
International Journal of Cancer
Epacadostat is a potent and highly selective inhibitor of indoleamine 2,3‐dioxygenase 1 (IDO1). Here we report results from the open‐label, dose‐escalation, Phase 1b ECHO‐110 study evaluating epacadostat plus atezolizumab in patients with pre
Autor:
Herbert Hurwitz, Vaibhav Sahai, Chris Verslype, Jason Clark, Johanna C. Bendell, Ashwin Reddy Sama, Eric Van Cutsem, Manuel Hidalgo, Edward W Greeno, Eileen M. O'Reilly, Chung Pin Li, Kenneth H. Yu, Christopher James Walker, Fitzroy Dawkins, Teresa Macarulla, Marcelo Garrido Salvo
Publikováno v:
Investigational New Drugs. 36:683-695
Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP]
Autor:
Hui-Ling Zhen, Jay Patel, Srdan Verstovsek, Jean-Jacques Kiladjian, Jason Gotlib, Alessandro M. Vannucchi, Philomena Colucci, Alessandro Rambaldi, William Shomali, Christopher James Walker, Andreas Reiter, Tracy I. George
Publikováno v:
Blood. 138:385-385
Background: MLN FGFR1 comprise rare hematologic neoplasms belonging to the World Health Organization major category of fusion tyrosine kinases typically associated with eosinophilia. MLN FGFR1 may present with chronic or blast phase (CP or BP) involv
Autor:
Sharon Shacham, Yosef Landesman, Leah Henegar, Kathleen Martyn, Christopher James Walker, Hua Chang, Trinayan Kashyap, Nicholas Fredette
Publikováno v:
Cancer Research. 81:1049-1049
Background: Decitabine (DEC) is a hypomethylating agent approved to treat acute myeloid leukemia (AML) that can reactivate tumor suppressor genes that are epigenetically silenced by DNA methylation. Selinexor (SEL) is a selective inhibitor of nuclear
Autor:
Andrea Napolitano, Sharon Shacham, Michael Kauffman, Jatin J. Shah, Hua Chang, Bruno Bolognese, Jianjun Liu, Bruno Vincenzi, Christopher James Walker, Yosef Landesman
Publikováno v:
Journal of Clinical Oncology. 39:11509-11509
11509 Background: Patients (pts) with recurrent inoperative DDLS have a poor prognosis and limited treatment options. Selinexor is an oral, selective inhibitor of nuclear export (SINE) compound approved for previously treated pts with myeloma and dif
Autor:
Christopher James Walker, Jatin J. Shah, Shirong Li, Yi Chai, Yosef Landesman, Sharon Shacham, Suzanne Lentzsch
Publikováno v:
Journal of Clinical Oncology. 39:8027-8027
8027 Background: Activating mutations of the RAS genes NRAS, KRAS, and HRAS ( RASmut) occur in up to 50% of MM and portend poor survival and high recurrence rates. MM cells with RASmut are susceptible to inhibition of germinal center kinase (GCK), re
Autor:
Stacy Fechner, Leah Henegar, Thaddeus J. Unger, Patricia Cogswell, Yosef Landesman, Sharon Shacham, Trinayan Kashyap, Christopher James Walker, Michael M. Wick, Hua Chang, Joan Levy
Publikováno v:
Journal of Clinical Oncology. 38:e23502-e23502
e23502 Background: Selinexor is a selective inhibitor of nuclear export that inhibits XPO1 from shuttling its cargo from the nucleus to the cytoplasm. This leads to accumulation of tumor suppressor proteins in the nucleus, activation of cell cycle ch
Autor:
Yosef Landesman, Mariano J. Alvarez, Patrick Y. Wen, Yao Shen, Martin J. van den Bent, Andrew B. Lassman, Sharon Shacham, Scott R. Plotkin, Anna Maria Elisabeth Walenkamp, Hua Chang, Morten Mau-Sørensen, Adam L. Green, Leah Henegar, Christopher James Walker, Andrea Califano
Publikováno v:
Journal of Clinical Oncology. 38:2565-2565
2565 Background: The nuclear export protein exportin 1 (XPO1) is overexpressed in many cancers, including GBM. Selinexor is an inhibitor of XPO1 that crosses the blood-brain-barrier and targets cancer cells by sequestering tumor suppressor proteins a
Autor:
Fitzroy Dawkins, Kenneth H. Yu, Eric Van Cutsem, Edward W Greeno, Johanna C. Bendell, Eileen M. O'Reilly, Chung-Pin Li, Marcelo Garrido, Vaibhav Sahai, Manuel Hidalgo, Chris Verslype, Jason Clark, Ashwin Reddy Sama, Christopher James Walker, Teresa Macarulla, Herbert Hurwitz
Publikováno v:
Journal of Clinical Oncology. 35:343-343
343 Background: The JAK-STAT pathway plays a role in the pathogenesis of PC. In a phase 2 study, the JAK1/2 inhibitor Rux + C improved OS vs C alone in mPC pts with evidence of systemic inflammation. Methods: In two phase 3 studies, advanced/mPC pts
Autor:
Johanna C. Bendell, Christopher James Walker, Kimberli J. Brill, Jason Clark, Fitzroy Dawkins, Eileen M. O'Reilly
Publikováno v:
Journal of Clinical Oncology. 33:TPS4146-TPS4146
TPS4146 Background: The systemic inflammatory response characteristic of PC is mediated in part by JAK-STAT signaling and may contribute to local tumor growth and disease-related weight loss, decre...